Publications

Detailed Information

Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: A single institution experience

DC Field Value Language
dc.contributor.authorKim, Hee Seung-
dc.contributor.authorKim, Jae Weon-
dc.contributor.authorWu, Hong Gyun-
dc.contributor.authorChung, Hyun Hoon-
dc.contributor.authorSong, Yong Sang-
dc.contributor.authorLee, Hyo Pyo-
dc.contributor.authorKang, Soon Beom-
dc.contributor.authorPark, Noh Hyun-
dc.date.accessioned2012-06-04T08:55:52Z-
dc.date.available2012-06-04T08:55:52Z-
dc.date.issued2010-06-
dc.identifier.citationJOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH; Vol.36 3; 598-604ko_KR
dc.identifier.issn1341-8076-
dc.identifier.urihttps://hdl.handle.net/10371/76811-
dc.description.abstractAim: We sought to compare survival and toxicity between paclitaxel/carboplatin (TC) and doxorubicin/cisplatin (AP) for concurrent chemoradiation (CCR) in intermediate- or high-risk endometrioid endometrial cancer. Methods: The clinical data of 40 patients with intermediate- (FIGO stage IC-IIB, n = 12) or high-risk endometrioid endometrial cancer (FIGO stage IIIA-IVA, n = 28) were reviewed retrospectively between March 2000 and December 2007, who were treated with TC (n = 23, group 1) or AP (n = 17, group 2) for CCR after surgery. Results: Progression-free survival (PFS) and overall survival (OS) were not different between groups 1 and 2 (median PFS and OS; 35 vs 24 and 76 vs 39 months, respectively, P > 0.05). However, >= 6 cycles of chemotherapy improved PFS compared with 3-5 cycles of chemotherapy (51 vs 21 months, P = 0.04), suggesting that >= 6 cycles of chemotherapy was an independent prognostic factor improving PFS (adjusted HR, 0.27; 95% CI, 0.08 to 0.91; P = 0.04). Grade 3 or 4 hematological and non-hematological, especially, gastrointestinal, toxicities related with chemotherapy during CCR were more common in group 2 than in group 1, whereas there was no difference in grade 3 or 4 late complication by CCR between the 2 groups. Conclusion: These findings suggest that TC may have comparable efficacy to AP for CCR with lesser toxicity, and >= 6 cycles of chemotherapy may be more beneficial than 3-5 cycles of chemotherapy in intermediate- or high-risk endometrioid endometrial cancer. However, large-scale randomized controlled trials are needed to support these results.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELL PUBLISHING, INCko_KR
dc.subjectcarboplatinko_KR
dc.subjectcisplatinko_KR
dc.subjectdoxorubicinko_KR
dc.subjectpaclitaxelko_KR
dc.subjectendometrioid endometrial cancerko_KR
dc.titleComparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: A single institution experienceko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김희승-
dc.contributor.AlternativeAuthor김재원-
dc.contributor.AlternativeAuthor우홍균-
dc.contributor.AlternativeAuthor정현훈-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor송용상-
dc.contributor.AlternativeAuthor강순범-
dc.contributor.AlternativeAuthor이효표-
dc.identifier.doi10.1111/j.1447-0756.2010.01223.x-
dc.citation.journaltitleJOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH-
dc.description.citedreferenceKim K, 2009, J GYNECOL ONCOL, V20, P203, DOI 10.3802/jgo.2009.20.4.203-
dc.description.citedreferenceHogberg T, 2008, CLIN ONCOL-UK, V20, P463, DOI 10.1016/j.clon.2008.04.001-
dc.description.citedreferenceSorbe B, 2008, INT J GYNECOL CANCER, V18, P803, DOI 10.1111/j.1525-1438.2007.01094.x-
dc.description.citedreferenceLEE HP, 2008, KOREAN J OBSTET GYNE, V51, P1411-
dc.description.citedreference*PORTEC 3, 2008, PORTEC3-
dc.description.citedreference*GOG, 2008, 209 GOG-
dc.description.citedreference*RTOG, 2008, 9905GOG0194 RTOG-
dc.description.citedreferenceHumber CE, 2007, ANN ONCOL, V18, P409, DOI 10.1093/annonc/mdl417-
dc.description.citedreferenceLupe K, 2007, INT J RADIAT ONCOL, V67, P110, DOI 10.1016/j.ijrobp.2006.08.006-
dc.description.citedreferenceSovak MA, 2007, INT J GYNECOL CANCER, V17, P197, DOI 10.1111/j.1525-1438.2006.00746.x-
dc.description.citedreferenceHOGBERG T, 2007, J CLIN ONCOL, V25-
dc.description.citedreferenceFODA I, 2007, J EGYPT NATL CANC I, V19, P163-
dc.description.citedreferenceCreasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105-
dc.description.citedreferenceGreven K, 2006, GYNECOL ONCOL, V103, P155, DOI 10.1016/j.ygyno.2006.02.007-
dc.description.citedreferenceGadducci A, 2006, CRIT REV ONCOL HEMAT, V58, P242, DOI 10.1016/j.critrevonc.2005.11.002-
dc.description.citedreferenceHidaka T, 2006, J OBSTET GYNAECOL RE, V32, P330, DOI 10.1111/j.1447-0756.2006.00405.x-
dc.description.citedreferenceMangili G, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2407-6-198-
dc.description.citedreferenceMichener CM, 2005, J CANCER RES CLIN, V131, P581, DOI 10.1007/s00432-005-0676-x-
dc.description.citedreferenceAkram T, 2005, AM J OBSTET GYNECOL, V192, P1365, DOI 10.1016/j.ajog.2004.12.032-
dc.description.citedreferenceKuwabara Y, 2005, JPN J CLIN ONCOL, V35, P23, DOI 10.1093/jjco/hyi003-
dc.description.citedreferenceThigpen JT, 2004, J CLIN ONCOL, V22, P3902, DOI 10.1200/JCO.2004.02.088-
dc.description.citedreferenceSoper JT, 2004, GYNECOL ONCOL, V95, P95, DOI 10.1016/j.ygyno.2004.06.041-
dc.description.citedreferenceFleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184-
dc.description.citedreferenceKeys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048-
dc.description.citedreferenceAapro MS, 2003, ANN ONCOL, V14, P441, DOI 10.1093/annonc/mdg112-
dc.description.citedreferenceCreutzberg CL, 2000, LANCET, V355, P1404-
dc.description.citedreferenceOKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649-
dc.description.citedreferenceAALDERS J, 1980, OBSTET GYNECOL, V56, P419-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share